Tag: Nuvalent
-
Why Big Pharma Is Buying Biotech Again: The Patent Cliff Explained
Patent expirations are reshaping the pharmaceutical industry. Here’s why Big Pharma is buying biotech companies again—and what investors should watch next.
-
Can GSK Deliver Its £40 Billion Growth Ambition?
GlaxoSmithKline (GSK) will unveil its long-term growth strategy on July 28. As CEO Luke Miels leads his first major investor event, the focus will be on whether oncology expansion and HIV transformation can realistically support the company’s £40 billion revenue ambition by 2031.